317 related articles for article (PubMed ID: 17721616)
1. Fibrin clot structure in patients with end-stage renal disease.
Sjøland JA; Sidelmann JJ; Brabrand M; Pedersen RS; Pedersen JH; Esbensen K; Standeven KF; Ariëns RA; Gram J
Thromb Haemost; 2007 Aug; 98(2):339-45. PubMed ID: 17721616
[TBL] [Abstract][Full Text] [Related]
2. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
Undas A; Kolarz M; Kopeć G; Tracz W
Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
[TBL] [Abstract][Full Text] [Related]
3. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
4. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W
Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
[TBL] [Abstract][Full Text] [Related]
5. The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome.
Undas A; Nycz K; Pastuszczak M; Stompor T; Zmudka K
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):522-7. PubMed ID: 20479639
[TBL] [Abstract][Full Text] [Related]
6. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
[TBL] [Abstract][Full Text] [Related]
8. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.
Kirmizis D; Tsiandoulas A; Pangalou M; Koutoupa E; Rozi P; Protopappa M; Barboutis K
Med Sci Monit; 2006 Feb; 12(2):CR55-62. PubMed ID: 16449948
[TBL] [Abstract][Full Text] [Related]
9. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
10. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
Gronostaj K; Richter P; Nowak W; Undas A
Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
[TBL] [Abstract][Full Text] [Related]
11. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
Celińska-Lowenhoff M; Iwaniec T; Padjas A; Musiał J; Undas A
Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
[TBL] [Abstract][Full Text] [Related]
12. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.
Undas A; Szułdrzynski K; Stepien E; Zalewski J; Godlewski J; Tracz W; Pasowicz M; Zmudka K
Atherosclerosis; 2008 Feb; 196(2):551-7. PubMed ID: 17640649
[TBL] [Abstract][Full Text] [Related]
13. Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism.
Palka I; Nessler J; Nessler B; Piwowarska W; Tracz W; Undas A
Heart; 2010 Jul; 96(14):1114-8. PubMed ID: 20610458
[TBL] [Abstract][Full Text] [Related]
14. Effect of ioxaglate--an ionic low osmolar contrast medium--on fibrin polymerization in vitro.
Brass O; Belleville J; Sabattier V; Corot C
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):689-97. PubMed ID: 8292718
[TBL] [Abstract][Full Text] [Related]
15. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication.
Bhasin N; Ariëns RA; West RM; Parry DJ; Grant PJ; Scott DJ
J Vasc Surg; 2008 Dec; 48(6):1497-503, 1503.e1. PubMed ID: 18829228
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation and fibrin clot structure.
Wolberg AS
Blood Rev; 2007 May; 21(3):131-42. PubMed ID: 17208341
[TBL] [Abstract][Full Text] [Related]
17. Decreased fibrinolytic potential and morphological changes of fibrin structure in dermatitis herpetiformis.
Görög A; Németh K; Szabó L; Mayer B; Silló P; Kolev K; Kárpáti S
J Dermatol Sci; 2016 Oct; 84(1):17-23. PubMed ID: 27440075
[TBL] [Abstract][Full Text] [Related]
18. Interpretation and Validation of Maximum Absorbance Data Obtained from Turbidimetry Analysis of Plasma Clots.
Pieters M; Guthold M; Nunes CM; de Lange Z
Thromb Haemost; 2020 Jan; 120(1):44-54. PubMed ID: 31752041
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability.
Flood VH; Nagaswami C; Chernysh IN; Al-Mondhiry HA; Weisel JW; Farrell DH
Br J Haematol; 2007 Jul; 138(1):117-24. PubMed ID: 17555455
[TBL] [Abstract][Full Text] [Related]
20. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system.
Ajjan RA; Standeven KF; Khanbhai M; Phoenix F; Gersh KC; Weisel JW; Kearney MT; Ariëns RA; Grant PJ
Arterioscler Thromb Vasc Biol; 2009 May; 29(5):712-7. PubMed ID: 19286636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
